ES2434853B1 - Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos - Google Patents

Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos Download PDF

Info

Publication number
ES2434853B1
ES2434853B1 ES201230919A ES201230919A ES2434853B1 ES 2434853 B1 ES2434853 B1 ES 2434853B1 ES 201230919 A ES201230919 A ES 201230919A ES 201230919 A ES201230919 A ES 201230919A ES 2434853 B1 ES2434853 B1 ES 2434853B1
Authority
ES
Spain
Prior art keywords
methods
stem cell
therapeutic
mir
molecular marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
ES201230919A
Other languages
English (en)
Other versions
ES2434853A1 (es
Inventor
Manuel Ángel GONZÁLEZ DE LA PEÑA
Antonio Bernad Miana
María TOMÉ PIZARRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Original Assignee
Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III filed Critical Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III
Priority to ES201230919A priority Critical patent/ES2434853B1/es
Priority to PCT/ES2013/070381 priority patent/WO2013186418A1/es
Publication of ES2434853A1 publication Critical patent/ES2434853A1/es
Application granted granted Critical
Publication of ES2434853B1 publication Critical patent/ES2434853B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos.#La presente invención se relaciona con métodos para determinar la capacidad inmunorreguladora de una célula madre, basándose en los niveles de expresión del microARN miR-335. Adicionalmente, la invención también se relaciona con métodos in vitro para incrementar la capacidad inmunorreguladora de una célula madre, en donde dichos métodos comprenden tratar dicha célula madre con un inhibidor de miR-335. Finalmente, la invención se relaciona con usos y métodos terapéuticos para tratar a un sujeto con una enfermedad autoinmune, una enfermedad inflamatoria, la enfermedad de injerto contra huésped, o una enfermedad que requiera la inducción de tolerancia a un trasplante o la regeneración y/o reparación de tejidos, comprendiendo dichos usos y métodos terapéuticos la administración de una célula madre que presenta niveles reducidos de expresión y/o actividad de miR-335.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
ES201230919A 2012-06-12 2012-06-12 Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos Withdrawn - After Issue ES2434853B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201230919A ES2434853B1 (es) 2012-06-12 2012-06-12 Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos
PCT/ES2013/070381 WO2013186418A1 (es) 2012-06-12 2013-06-12 Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230919A ES2434853B1 (es) 2012-06-12 2012-06-12 Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos

Publications (2)

Publication Number Publication Date
ES2434853A1 ES2434853A1 (es) 2013-12-17
ES2434853B1 true ES2434853B1 (es) 2014-09-30

Family

ID=49034107

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230919A Withdrawn - After Issue ES2434853B1 (es) 2012-06-12 2012-06-12 Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos

Country Status (2)

Country Link
ES (1) ES2434853B1 (es)
WO (1) WO2013186418A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699524B (zh) * 2016-02-26 2019-12-10 Scm生命科学有限公司 调节t细胞介导性疾病的预防或治疗用药剂学组合物
CN111979187B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种抗人间充质干细胞衰老及增强其干性特征的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
JP2909216B2 (ja) 1994-04-29 1999-06-23 パーキン‐エルマー コーポレイション 核酸増幅生成物のリアルタイム検出装置
DE69638321D1 (de) 1995-10-11 2011-03-03 Luminex Corp Gleichzeitige mehrfachanalyse klinischer proben
US6057134A (en) 1996-10-07 2000-05-02 Ambion, Inc. Modulating the efficiency of nucleic acid amplification reactions with 3' modified oligonucleotides
CA2281205A1 (en) 1997-02-12 1998-08-13 Eugene Y. Chan Methods and products for analyzing polymers
US6365731B1 (en) 1997-08-06 2002-04-02 Ambion, Inc. Stripping nucleic acids with iodine and sodium thiosulfate
JP4357112B2 (ja) 1997-10-14 2009-11-04 ルミネックス コーポレイション 精密蛍光染色された粒子及びその製造及び使用方法
US6458583B1 (en) 1998-09-09 2002-10-01 Agilent Technologies, Inc. Method and apparatus for making nucleic acid arrays
US6461812B2 (en) 1998-09-09 2002-10-08 Agilent Technologies, Inc. Method and multiple reservoir apparatus for fabrication of biomolecular arrays
US6436640B1 (en) 1999-03-18 2002-08-20 Exiqon A/S Use of LNA in mass spectrometry
US6465183B2 (en) 1999-07-01 2002-10-15 Agilent Technologies, Inc. Multidentate arrays
US6461816B1 (en) 1999-07-09 2002-10-08 Agilent Technologies, Inc. Methods for controlling cross-hybridization in analysis of nucleic acid sequences
AU6779700A (en) 1999-08-17 2001-03-13 Luminex Corporation Microparticles with multiple fluorescent signals and methods of using same
US7122303B2 (en) 1999-09-17 2006-10-17 Agilent Technologies, Inc. Arrays comprising background features that provide for a measure of a non-specific binding and methods for using the same
US6428957B1 (en) 1999-11-08 2002-08-06 Agilent Technologies, Inc. Systems tools and methods of assaying biological materials using spatially-addressable arrays
AU2002334307A1 (en) 2001-09-04 2003-03-18 Exiqon A/S Novel lna compositions and uses thereof
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
WO2013186418A1 (es) 2013-12-19
WO2013186418A9 (es) 2014-04-17
ES2434853A1 (es) 2013-12-17

Similar Documents

Publication Publication Date Title
ES2533145B1 (es) Procedimiento cosmético para reducir el tejido adiposo subcutáneo
CO2018003678A2 (es) Composiciones y métodos para inhibir la expresión génica de lpa
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
WO2014028493A3 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
ES2721180T3 (es) Productos terapéuticos usando células adiposas y secreciones celulares
AR091388A1 (es) Diferenciacion de celulas madres embrionicas humanas en celulas endocrinas pancreaticas
BR112014005355A2 (pt) células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença
CL2015000529A1 (es) Inhibidores de glucosilceramida sintasa.
CU24495B1 (es) Compuestos que expanden las células hematopoyéticas y método ex vivo para expandir las células hematopoyéticas
DOP2013000025A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CL2010000710A1 (es) Uso de una canula para la irradiacion de un objetivo en un ojo,en que la canula esta configurada ser insertada en un espacio potencial debajo de la capsula de tenon del ojo, la insercion de la canula permite la observacion a traves de la pupila, puede ser ajustada y permite la irradiacion del objetivo con rbs.
BR112018003031A2 (pt) formulações clínicas
WO2013124815A3 (en) Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
MX363000B (es) Composiciones y usos de las mismas para tratar la inflamación.
CY1124195T1 (el) Συμπληρωματικα θεραπευτικα σκευασματα για την διαδοχικη ή ξεχωριστη χορηγηση βουτυρικου οξεος και προβιοτικων
BR112016029558A2 (pt) terapia de células-tronco em patologias endometriais
CR20150310A (es) Solución para preservar conductos vasculares
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
WO2014138315A8 (en) Heparanase expression in human t lymphocytes
AR108134A1 (es) Diferenciación de células madre pluripotentes en células del endodermo del intestino medio
CL2016001510A1 (es) Células madre derivadas de musculo de mamifero
BR112017019189A2 (pt) agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
ES2434853B1 (es) Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos
CL2015003402A1 (es) Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas
CY1122042T1 (el) Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2434853

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140930

FA2A Application withdrawn

Effective date: 20150209